Effect of age on outcome with primary angioplasty versus thrombolysis
David R. Holmes, Jr., MD, FACC*,
Harvey D. White, DSc, FACC ,
Karen S. Pieper, MS ,
Stephen G. Ellis, MD, FACC ,
Robert M. Califf, MD, FACC and
Eric J. Topol, MD, FACC
* Mayo Clinic and Foundation, Rochester, Minnesota, USA
Green Lane Hospital, Auckland, New Zealand
Duke Clinical Research Institute, Durham, North Carolina, USA
Cleveland Clinic Foundation, Cleveland, Ohio, USA
View larger version (19K):
[in a new window]
|
Figure 1 Age distribution of patients in the percutaneous transluminal coronary angioplasty (PTCA) substudy, by treatment group (angioplasty or tissue-type plasminogen activator [t-PA]) and by age decile.
|
|
View larger version (18K):
[in a new window]
|
Figure 2 The primary outcome, 30-day mortality and/or reinfarction (A), and its components, 30-day mortality (B) and 30-day reinfarction (C), by treatment group and by age decile. Abbreviations as in Figure 1.
|
|
View larger version (21K):
[in a new window]
|
Figure 3 Thirty-day mortality or disabling stroke (A) and 30-day mortality, disabling stroke or reinfarction (B), by treatment group and by age decile. Abbreviations as in Figure 1.
|
|
View larger version (17K):
[in a new window]
|
Figure 4 Probabilities of 30-day death and/or reinfarction (A) and of 30-day death, reinfarction or disabling stroke (B). Abbreviations as in Figure 1.
|
|
View larger version (18K):
[in a new window]
|
Figure 5 Mortality rates over 6 months for 50-year old patients and for 70-year old patients, by treatment group. Abbreviations as in Figure 1.
|
|
|
